Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
You will arrive for your appointment on day one already in mild withdrawal
GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide, Others), By Application (Type 2 Diabetes Mellitus, Chronic Weight Management, Cardiovascular Risk Reduction, Others), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034 Last Updated: July 17, 2026 | Author: Pavan Warade | Format: | Report Code: SR8134DR | Pages: 200 GLP-1 Receptor Agonist Market Size & Growth Analysis The GLP-1 receptor agonist market size was valued at USD 56.34 billion in 2025 and is projected to grow from USD 63.24 billion in 2026 to USD 161.40 billion by 2034, registering a CAGR of 12.43% during the forecast period (20262034)
Some GLP-1 medications (specifically liraglutide, semaglutide and dulaglutide) have demonstrated cardiovascular benefits in certain patient populations with type 2 diabetes
Ipamorelin is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor and a growth hormone secretagogue
